Your Vision, Our Innovations, Clinical Reality!

Our Inference-based AI technology empowers scientists to quickly identify better therapeutic candidates with lower cost, which have low failure risks in drug-like properties and toxicity, improving success rates in clinical trials.

Boosting Drug Candidates' Success in Clinical Trials

According to the clinical trial results from 2010 to 2017, 90% of drug candidates failed in clinical trials. And 45% of failures are resulted from poor absorption, distribution, metabolism, excretion properties and toxicity of candidates [Sun et al. Acta Pharmaceutica Sinica B 2022, 12: 3049-3062].

Proholistic Discovery is a pioneer in providing a comprehensive systems approach with inference-based AI approach to guide drug discovery to avoid these failures and towards successful clinical trials. Our cutting-edge technology focuses on providing Pharmacokinetics, Pharmacodynamics, and Systems pharmacology modeling and assessment.

Learn More or Get a Quote

Our Services

Consultation

Our consultation services offer expert guidance in systems pharmacology to optimize drug development strategies.

We work with Applied Pharmaceutical Innovation (API) based in Edmonton to provide tailored solutions to enhance success rates and streamline the clinical trial process, ensuring efficient and effective outcomes.

We partner with a US-based Praexisio Inc ., a leader in structural biology, bioinformatics, and drug design to provide a generative AI-guided molecule design and modification service. Together, we empower clients to either create innovative molecules or enhance existing ones to meet their specific needs.

Bayesian AI ADMET assessment

Our solution to increase clinical success.

Bayesian AI ADMET assessment. It provides a quick and yet robust estimate of the ADMET properties of your candidates.
Customized Physiological based PKPD modeling.
- Animal PBPK/PD model tailored to your needs, validated with benchmark studies
- Include a virtual course to set up and conduct in silico studies independently

Aptamer design

We offer a cutting-edge, proprietary technology for aptamer design—a faster, smarter alternative to traditional SELEX-based selection. Our AI-driven approach rapidly designs highly specific RNA/DNA aptamers for any biomolecular target, including small molecules, proteins, nucleic acids, and phospholipids, in under two weeks. This breakthrough accelerates discovery and development, saving both time and resources.

Learn More or Get a Quote

Our commitment

Innovation

Our commitment to innovation drives us to explore new horizons in quantitative systems pharmacology. We constantly seek groundbreaking solutions to revolutionize the industry and help clients advancing their drug discovery.

Collaboration

Collaboration lies at the heart of our approach. By fostering strong partnerships with clients and industry experts, we create synergies that lead to enhanced drug development processes and ultimately, improved clinical trial success.

Quality

Quality is paramount in everything we do. From our services to our technology, we uphold the highest standards to deliver excellence and reliability in supporting drug development initiatives.

Meet Our Team

Our dedicated team at Proholistic Discovery brings over 30 years of expertise in biomedical sciences and computer-aided drug discovery.

Richard, Chih-Yuan Tseng

President

Richard is a seasoned theoretical and information physicist with 15+ years of experience in both academic and industrial research and development in computational biology and preclinical drug discovery. Specifically, he is specialized in information theory approach for drug discovery, fragment-based aptamer design, pharmacokinetic and pharmacodynamic modeling and simulations. He has published over 30 peer-reviewed papers and book chapters. He also owns 8 patents. He has headed a computational group of an Edmonton-based natural therapy company to develop company’s core technology for combination drug discovery using systems pharmacology and information theory approach. He co-founded two biotech companies.

Jack Tuszynski

Chief Scientific Officer

Jack has been a professor of physics of the University of Alberta, Canada since 1988 and professor of bioengineering at the Polytechnic University of Turin, Italy since 2017. Between 2005 and 2020 he held the prestigious Allard Chair in Experimental Oncology at the Cross Cancer Institute. He held visiting professorship and research positions in China, Germany, France, Israel, Denmark, Belgium, Poland and Switzerland. He has published 600 journal papers, and 12 books. He obtained 7 patents in the USA, Canada, EU, South Korea, Brazil, Japan and Singapore. His received over 100 research grants from Canadian, US and European funding agencies. He is on the editorial board of 30 international journals. His molecular biophysics group performs research in drug design for a spectrum of applications. One of the drugs (CCI-001) he designed is in clinical trials for metastatic bladder cancer. He was a founding member of 3 spin-off companies.